A recent publication from the RisCoin study demonstrated impaired humoral responses to COVID-19 mRNA vaccination in patients with IBD receiving immunosuppressive therapies targeting tumor necrosis factor-alpha compared to other commonly used biologics for IBD [24]. This evidence concerns the gene TNF and COVID-19.